News & Videos - AVEXIS INC.

SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis Temperature Sensitive Gene Therapy Protected by Cloud-Connected Smart Shipper and evo.is Cloud App for Real Time Distribution Visibility and Management PR Newswire ALBUQUERQUE, N.M., Nov. 5, 2018 ALBUQUERQUE, N.M. , Nov. 5, 2018 /PRNewswire/ -- SAVSU Technologies, a leading developer and supplier of precision cloud-connected thermal shipping containers and the most advanced cold chain visibility platform ("SAVSU"), today...

-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be held in June 2018 -- CHICAGO, May 03, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the first quarter ended March 31, 2018, recent...

CHICAGO, May 01, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the proposed acquisition of AveXis by Novartis AG (Novartis) expired at 11:59 p.m. on April 30, 2018. On April 6, 2018, AveXis, Novartis and Novartis AM Merger...

CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the first patient has been dosed in a Phase 3 trial evaluating AVXS-101 in pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3 (SPRINT). “Treating SMA as early as possible is critically important in order to rescue motor neurons before...

– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial were alive and event-free at 24-month follow-up – – Patients observed in long-term follow-up from the Phase 1 trial continued to gain strength and achieve new milestones, including two additional patients who could stand with assistance – CHICAGO, April 24, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc....

RM LAW Announces Investigation of AveXis, Inc. PR Newswire BERWYN, Pa., April 19, 2018 BERWYN, Pa. , April 19, 2018 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of AveXis, Inc. ("AveXis" or the "Company") (NASDAQ: AVXS) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Novartis in a transaction valued at approximately $8.7 billion . If you own shares of AveXis and...

CHICAGO, April 19, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that initial results from the pivotal study (STR1VE) of AveXis’ proprietary gene therapy, AVXS-101, for the treatment of spinal muscular atrophy (SMA) Type 1, and 24-month follow-up data from the Phase 1 trial, will be presented at the 2018 Annual Meeting of the...

WEISSLAW LLP Investigates AveXis Inc. Acquisition PR Newswire NEW YORK, April 11, 2018 NEW YORK , April 11, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of AveXis Inc. ("AVXS" or the "Company") (NASDAQ: AVXS) in connection with the proposed acquisition of the Company by Novartis AG ("Novartis"). Under the terms of the acquisition agreement, the Company's shareholders will receive $218.00 in cash for...

Novartis to acquire AveXis for $218 per share in cash AveXis’ lead product candidate, AVXS-101, expected to enhance Novartis’s position as a gene therapy and neuroscience leader Transaction expected to be completed in mid-2018 CHICAGO, April 09, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) announced today that it has entered into an agreement and plan of merger with Novartis pursuant to which Novartis will acquire AveXis for $218 per share or a total of $8.7 billion in cash. This...

CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) awarded the company’s initial product candidate, AVXS-101, SAKIGAKE Designation (SAKIGAKE) for the treatment of spinal muscular atrophy (SMA) Type 1. The designation was based on data from the Phase 1...

– On track to request pre-BLA meeting with FDA in Q2 2018 – – Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of 2018 – – Anticipates IND submissions for Rett syndrome and genetic ALS in late 2018/early 2019 – – Conference call and webcast February 27 at 4:30 p.m. EST – CHICAGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for...

NEW YORK, NY / ACCESSWIRE / February 27, 2018 / AveXis, Inc. (NASDAQ: AVXS ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/40003 To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor Network Investor...

CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will report financial and operating results for the fourth quarter and full year ended December 31, 2017, as well as recent corporate highlights, on Tuesday, February 27, 2018, after the close of U.S.-based financial markets. AveXis management will host a conference call and live...

– First patient has been dosed in pivotal trial of AVXS-101 for SMA Type 1 – – Conference call and webcast November 9 at 4:30 p.m. EST – CHICAGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the third quarter ended September 30, 2017, recent corporate highlights and upcoming milestones. “We...

CHICAGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will report financial and operating results for the third quarter ended September 30, 2017, on Thursday, November 9, 2017, after the close of U.S.-based financial markets. AveXis management will host a conference call and live webcast at 4:30 p.m. Eastern Standard Time. Analysts and...

– All patients were alive and event-free at 20 months of age as of the August 7, 2017 data cut-off – – Patients in Cohort 2 continue to demonstrate improvements in motor milestones – SAINT MALO, France, Oct. 03, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will report top-line data as of August 7, 2017, from the Phase 1 trial of AVXS-101...

– FDA notified AveXis it may initiate pivotal trial based on a review of data provided by the company following CMC Type B meeting – – Product used in the pivotal trial will be from the AveXis GMP manufacturing process; pivotal trial to commence immediately – – Conference call and webcast today at 8:00 a.m. EDT – CHICAGO, Sept. 29, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and...

CHICAGO, June 26, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,111,250 shares of its common stock at a price to the public of $70.00 per share before underwriting discounts and commissions, including 536,250 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The net proceeds to AveXis from the offering, after deducting the underwriting discounts...

CHICAGO, June 20, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,575,000 shares of its common stock. The net proceeds to AveXis from the offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by AveXis, are expected to be approximately $234.5 million. The offering is expected to close on or about June 26, 2017, subject to customary closing conditions. In addition, AveXis...

CHICAGO, June 19, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $200 million of shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Goldman Sachs & Co. LLC, Jefferies LLC and BofA Merrill Lynch are acting as...